User:Brittany Allen/Sandbox 1
From Proteopedia
| Line 1: | Line 1: | ||
<Structure load='2bka' size='500' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /> | <Structure load='2bka' size='500' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' /> | ||
==General Background Information== | ==General Background Information== | ||
| - | TIP30, also known as both CC3<ref name=" | + | TIP30, also known as both CC3<ref name="1">Yu X, Li Z, Wu WKK. TIP30: A Novel Tumor-Suppressor Gene. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics [Internet]. 2015;22(5):339–48. Available from: http://www.ingentaconnect.com/content/cog/or/2015/00000022/F0020005/art00013#<ref>2</ref> is a tat-interacting protein that functions as a tumor suppressor involved in cell growth, apoptosis, metastasis, DNA repair, metabolism and angiogenesis of tumor cells<ref>3,4,5</ref>. TIP30 acts as a transcription cofactor that can regulate gene expression<ref> 6</ref> and has both pro-apoptotic and anti-metastatic properties<ref>7</ref>. When the promoter of TIP30 is methylated, TIP30 becomes downregulated and associated with tumor prognosis<ref>2</ref>. It is thought that the tumor suppressor effect is the result of the inhibition of nuclear transport through binding with importin βs or by regulating transcription through interaction as a complex with a co-activator independent of AF-2 function and the c-myc gene<ref>8</ref>. Several studies have found that TIP30 may be linked to esophageal carcinoma, laryngeal carcinoma, glioma, pancreatic ductal adenocarcinoma, breast cancer, gastric cancer, gallbladder adenocarcinoma, lung cancer, and hepatocellular carcinoma<ref>1</ref>. |
Revision as of 02:40, 4 December 2017
|
Contents |
General Background Information
TIP30, also known as both CC3Cite error: Invalid <ref> tag;
name cannot be a simple integer. Use a descriptive title is a tat-interacting protein that functions as a tumor suppressor involved in cell growth, apoptosis, metastasis, DNA repair, metabolism and angiogenesis of tumor cells[1]. TIP30 acts as a transcription cofactor that can regulate gene expression[2] and has both pro-apoptotic and anti-metastatic properties[3]. When the promoter of TIP30 is methylated, TIP30 becomes downregulated and associated with tumor prognosis[4]. It is thought that the tumor suppressor effect is the result of the inhibition of nuclear transport through binding with importin βs or by regulating transcription through interaction as a complex with a co-activator independent of AF-2 function and the c-myc gene[5]. Several studies have found that TIP30 may be linked to esophageal carcinoma, laryngeal carcinoma, glioma, pancreatic ductal adenocarcinoma, breast cancer, gastric cancer, gallbladder adenocarcinoma, lung cancer, and hepatocellular carcinoma[6].
Structure
TIP30 is an evolutionary conserved gene located on human chromosome 11[7] . TIP30 has a molecular mass of 30 kd[8] and is composed of 242 amino acids[9]. TIP30 is composed of alpha helices, beta sheets, and loops (Movie). Through sequence analysis studies, it is thought that TIP30 may be a member of the SDR (substrate determining residue) family which contain a characteristic motif at their catalytic start sites[10]. The carboxyl terminus of TIP30 binds to the SDR substrate, while the amino terminus of TIP30 is the nucleotide cofactor-binding domain which has a characteristic Gly-X-X-Gly- X-X-Gly motif (where X can be any amino acid)[11]. Since SDR families have binding specificity for NADPH[12] and TIP30 contains a dehydrogenase reductase fold that contains binding specificity for NADPH[13]., the binding of NADPH may be important for the biological activity of TIP30 including interactions with importins as well as the c-myc system[14].
TIP30 is known to bind 4 ligands: NDP (NADPH Dihydro-nicotinamide-adenine-dinucleotide-phosphate), PE8 (3,6,9,12,15,18,21 heptatricosane-1,2,3-diol), GOL (glycerol), and SO4 (sulfate ion)[15]. The location these residues bind can be seen in ________. According to uniprot, TIP30 contains a nucleotide binding region between residues 19-52, as shown in ________, and a binding site at residue 131, as shown in______. When comparing _____ and ________, it can be observed that the ligands bind in the active regions and interact with the residues. Uniprot also noted that TIP30 can contain a mutagenic site at positions 28-31 (______), if this site is present there is a loss of proapoptotic and metastasis-inhibiting effects.
